Key Highlights

● First-half revenue was US$44.5 million, up 29.3% at constant currency.

● The net loss widened to US$120.4 million from US$82.5 million.

● Cash and bank balances fell to US$279.4 million from US$353.2 million.

● Research and development expenses rose to US$102.8 million.

Ascentage Pharma Group International (NASDAQ:AAPG), a Rockville, Maryland-datelined oncology drug developer, reported unaudited interim results for the six months ended 30 June 2026 on 19 August 2026. Its American depositary shares (ADSs) trade on the Nasdaq Global Market as AAPG, and its ordinary shares are listed in Hong Kong under the code 6855. According to the company's January 2025 listing announcement, each ADS represents four ordinary shares.

Revenue was US$44.5 million (RMB302.2 million), up 29.3% at constant currency from US$32.6 million, with product sales of US$41.6 million against US$29.7 million. The net loss widened to US$120.4 million (RMB817.0 million) from US$82.5 million, equal to a loss of US$0.32 per share versus US$0.24. The company used average exchange rates of RMB6.7851 per US dollar for 2026 and RMB7.1636 for 2025.

Spending and Cash

Research and development expenses rose to US$102.8 million from US$73.8 million, which management attributes to global clinical trials. Selling and distribution costs increased to US$33.4 million from US$19.2 million, mainly reflecting marketing of lisaftoclax, while administrative expenses were US$17.5 million versus US$13.9 million.

Cash and bank balances fell to US$279.4 million (RMB1,895.6 million) at 30 June 2026 from US$353.2 million at the end of 2025. That is a decline of roughly US$74 million. With a half-year net loss above US$120 million, the cash position makes future financing or partnership income a legitimate question for investors, although the release does not state a runway.

Revenue rose by about US$12 million, while research and development alone rose by roughly US$29 million, so the loss widened. That pattern is common among oncology developers that fund late-stage trials before products reach scale, but it leaves results sensitive to trial timing and sales uptake.

Two Commercial Medicines

Olverembatinib, a third-generation BCR-ABL1 tyrosine kinase inhibitor, is approved in China for chronic myeloid leukaemia patients with the T315I mutation or resistance or intolerance to earlier treatments, and is covered by the national reimbursement drug list. At 30 June 2026 it was available at 879 pharmacies and hospitals, including 394 hospitals.

Lisaftoclax, an oral Bcl-2 inhibitor, is approved by China's drug regulator for adults with chronic lymphocytic leukaemia or small lymphocytic lymphoma who have received at least one earlier systemic therapy, including a BTK inhibitor. It was on the formulary at 415 pharmacies and hospitals, 60 of them hospitals, and the company says it plans to seek national reimbursement listing during 2026.

Pipeline and Disclosed Milestones

The company lists Phase III programmes for olverembatinib, namely POLARIS-1 in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia, POLARIS-2 in previously treated chronic-phase CML and POLARIS-3 in SDH-deficient gastrointestinal stromal tumours. For lisaftoclax it lists GLORA, GLORA-2, GLORA-3 and GLORA-4 across leukaemia and myelodysplastic syndrome settings. Several of these have US and European regulatory clearance.

APG-3288, a BTK degrader, received US IND clearance in January 2026 and Chinese clearance in February 2026, and a global Phase I study is under way. Disclosed next steps are continued trial enrolment, studies on overcoming venetoclax resistance and the reimbursement application. The company also appointed Dr Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer.

Commercial Launches Have Not Yet Caught Up With Trial Spending

The figures show a company moving from development toward commercial scale in China while funding an expensive global trial programme, so growing sales have not yet narrowed the loss. Clinical outcomes, regulatory decisions and reimbursement terms remain uncertain, and the release gives no new-drug-application timetable.